Acne on Testosterone Cypionate: Week-by-Week Timeline of What to Expect

By
Published Updated Last reviewed
Medication safety clinical consultation image for Acne on Testosterone Cypionate: Week-by-Week Timeline of What to Expect

Acne on Testosterone Cypionate: Week-by-Week Timeline of What to Expect

At a glance

  • Incidence: Approximately 40% of men on TRT report acne; 6-8% develop moderate-to-severe lesions (Rastrelli & Maggi, 2015)
  • Onset: Typically weeks 2-6 after the first injection
  • Peak: Weeks 8-12, coinciding with the first plateau in serum testosterone
  • Spontaneous improvement: Months 4-6 in most patients without dose adjustment
  • First-line management: Topical benzoyl peroxide 2.5-5% or tretinoin 0.025-0.05% started prophylactically at week 2
  • Escalate when: Inflammatory nodules appear, lesions spread to chest or back, or there is no response after 12 weeks of topical therapy
  • Consider discontinuation or dose reduction when: Nodulo-cystic acne covers <20% body surface area and is refractory to oral antibiotics plus topical therapy

Why Testosterone Cypionate Causes Acne: The Mechanism in Brief

Testosterone Cypionate is an esterified form of testosterone that is cleaved to free testosterone after intramuscular injection. Free testosterone is then converted to dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase in the skin. DHT binds androgen receptors in sebaceous glands, triggering increased sebum production. Excess sebum mixes with keratinocyte debris, occludes the follicular canal, and provides the anaerobic environment that Cutibacterium acnes thrives in. The result is the full acne cascade: comedones first, then inflammatory papules, then pustules or nodules in susceptible individuals.

Sebaceous glands in the face, chest, and upper back carry the highest density of androgen receptors, which explains the distribution pattern seen on TRT. Patients who had acne during puberty have already demonstrated that their sebaceous glands are androgen-sensitive, and they face the highest recurrence risk on TRT.

Weeks 1-2: The Pre-Eruption Window

Most patients see nothing unusual in the first two weeks. Testosterone Cypionate has a half-life of approximately eight days, so serum levels are still climbing toward a meaningful steady state. Sebaceous glands require a sustained androgen signal before they upregulate sebum output measurably.

What you can do right now: This is the single most underused window in TRT acne management. Starting a non-prescription topical such as benzoyl peroxide 2.5% wash (used once daily at night) during weeks one and two reduces the commensal C. acnes burden before the sebum surge arrives. The American Academy of Dermatology's acne guideline gives benzoyl peroxide a Grade A recommendation as monotherapy for mild comedonal and papulopustular acne, and it costs under ten dollars a bottle.

Patients who had significant adolescent acne should tell their prescribing clinician at the initiation visit, not after lesions appear, so that a topical retinoid can be prescribed proactively.

Weeks 3-6: First Lesions Appear

This is when most patients first notice something. Serum testosterone has reached a functional level by week three on a standard 100-200 mg every-one-to-two-week injection protocol, and sebaceous output begins to increase. Rastrelli and Maggi (2015) documented acne onset in TRT cohorts clustering in this window, with facial T-zone and upper back being the first areas affected.

The lesions at this stage are primarily open and closed comedones (blackheads and whiteheads), occasionally with scattered papules. This is the easiest phase to treat and the one most commonly undertreated because patients assume the skin is "adjusting."

What to do at week 3-6 if you haven't started anything:

  • Add benzoyl peroxide 2.5-5% wash if you haven't already
  • Request a prescription for tretinoin 0.025% cream if comedone count is rising
  • Avoid switching to oil-based moisturizers or comedogenic sunscreens
  • Do not begin any new anabolic compounds (DHEA supplements included) during this window, as they add additional androgenic load

Injection timing matters here. Patients on a biweekly (every-two-week) injection schedule experience larger testosterone peaks and troughs than those on weekly injections. The peak serum testosterone after a 200 mg biweekly injection can exceed the upper reference range transiently, and that supraphysiologic spike is a direct driver of sebaceous activity. If you are on a biweekly protocol and acne is emerging in weeks three to six, ask your clinician whether switching to weekly 100 mg injections would reduce peak-related side effects. The Endocrine Society's 2018 Clinical Practice Guideline for Testosterone Therapy specifically acknowledges that more frequent, lower-dose injections reduce peak-and-trough variation.

Weeks 7-12: The Peak Phase

Weeks eight to twelve represent the highest-risk window for acne severity. By this point, serum testosterone has reached a genuine steady state across the injection cycle, and the sebaceous glands have had enough sustained androgen stimulation to meaningfully upregulate sebum production. Inflammatory papules and pustules become more common. Some patients who started with only comedones develop painful inflamed lesions during this phase.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials published in NEJM (2016) and associated reports, found acne and oily skin adverse events to be significantly more frequent in the testosterone group than placebo. The TTrials used testosterone gel rather than cypionate, but the androgen mechanism is identical; the delivery route changes pharmacokinetics, not skin biology.

Clinical decision points at weeks 8-12:

  • If you are on benzoyl peroxide alone and developing pustules: escalate to a combination product containing benzoyl peroxide plus a topical antibiotic (clindamycin 1% is first-line per the AAD guideline)
  • If you started tretinoin in weeks three to six, you may be experiencing the tretinoin "purge," a temporary increase in lesion count as comedones are pushed to the surface. This typically resolves by week 10-12 of tretinoin use.
  • If nodular lesions (<5 mm, deeply inflamed, painful) are appearing: a telehealth or in-person dermatology visit is appropriate now, not in another two months. Oral doxycycline 100 mg twice daily reduces inflammatory acne lesion counts by roughly 50% within six to eight weeks and is compatible with TRT.
  • If lesions are covering the chest and back in addition to the face: this is classified as moderate-to-severe acne and warrants a conversation about whether the current TRT dose is appropriate for your physiology.

Do not attempt to reduce testosterone dose unilaterally. Discuss it with your prescribing clinician. Dose reduction resolves acne but may also reduce therapeutic benefit, and that tradeoff needs to be individualized.

Months 4-6: The Expected Improvement Window

For the majority of patients who do not have severe acne, months four to six bring meaningful improvement without any dose change. The sebaceous glands appear to partially accommodate the new androgen environment, and the skin microbiome shifts in response to the elevated sebum milieu. This accommodation is not complete for everyone, but the clinical literature consistently shows that TRT-associated acne is at its worst in the first three months.

A prospective cohort described by Bachman et al. (2010) in men receiving testosterone therapy found that acne adverse events were most frequently reported in months one through three, with a declining trend thereafter in patients managed with standard topical regimens.

If your acne has not begun to improve by month four despite consistent topical therapy, escalation options include:

  1. Oral doxycycline (100 mg twice daily for 12 weeks, then reassess)
  2. Topical adapalene 0.3% gel, which has stronger evidence than tretinoin for inflammatory acne and is now available over the counter in the US
  3. Isotretinoin (oral), reserved for nodulo-cystic or scarring acne refractory to two courses of oral antibiotics. Isotretinoin is the only intervention that produces long-term remission in severe acne; a course does not require stopping TRT, though your dermatologist should know you are on exogenous androgens.

Month 6 and Beyond: Long-Term Outlook

Patients who reach month six on TRT with well-controlled acne generally maintain that control. New flares can occur if the TRT dose is increased, if an injection is given late (causing a supraphysiologic compensatory peak), or if an androgen-containing supplement (creatine does not apply here, but prohormones or DHEA do) is added.

Patients who develop persistent moderate-to-severe acne beyond six months should have their free testosterone and DHT levels checked. Supraphysiologic DHT, not just total testosterone, is the proximate driver of sebaceous hyperactivity. If DHT is elevated above the reference range, a 5-alpha-reductase inhibitor such as finasteride 1 mg/day reduces sebaceous androgen activity, though it carries its own side-effect profile that requires separate discussion with your prescribing clinician.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Rastrelli G, Maggi M. "Erectile dysfunction as a sentinel of men's health." World Journal of Men's Health. 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650052/
  2. Snyder PJ, Bhasin S, et al. "Effects of testosterone treatment in older men." New England Journal of Medicine. 2016. https://www.nejm.org/doi/full/10.1056/NEJMoa1506119
  3. Bhasin S, et al. "Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology & Metabolism. 2018. https://academic.oup.com/jcem/article/103/5/1715/4939465
  4. Zaenglein AL, et al. "Guidelines of care for the management of acne vulgaris." Journal of the American Academy of Dermatology. 2016. https://www.jaad.org/article/S0190-9622(15)02614-6/fulltext
  5. Bachman E, et al. "Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis." Journal of Clinical Endocrinology & Metabolism. 2010. https://pubmed.ncbi.nlm.nih.gov/20554952/
  6. Kircik LH. "Doxycycline and its role in the treatment of acne." Journal of Drugs in Dermatology. 2010. https://pubmed.ncbi.nlm.nih.gov/20684150/
  7. Cutibacterium acnes pathogenesis overview. StatPearls, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK459173/